GSK CEO Emma Walmsley Reports Shareholding Transaction
Ticker: GLAXF · Form: 6-K · Filed: Jul 16, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 16, 2024 |
| Risk Level | low |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $38.9000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, shareholding
TL;DR
GSK CEO Walmsley filed an initial shareholding notice. Nothing major, but good to track.
AI Summary
On July 16, 2024, GSK plc filed a Form 6-K reporting a transaction notification regarding shareholdings. Emma Walmsley, the Chief Executive Officer, made an initial notification concerning her shareholding.
Why It Matters
This filing provides transparency into the shareholding activities of key executives, which can be an indicator of insider confidence in the company's performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of executive shareholding and does not indicate any significant operational or financial changes.
Key Players & Entities
- GSK plc (company) — Registrant
- Emma Walmsley (person) — Chief Executive Officer
FAQ
What type of filing is this?
This is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who is the subject of the transaction notification?
The transaction notification is regarding Emma Walmsley, the Chief Executive Officer of GSK plc.
What is the nature of the filing by Emma Walmsley?
Emma Walmsley made an initial notification regarding her shareholding.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 980 Great West Road, Brentford, Middlesex, TW8 9GS.
Does GSK plc file annual reports under Form 20-F or 40-F?
GSK plc indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 3,335 words · 13 min read · ~11 pages · Grade level 15.9 · Accepted 2024-07-16 10:44:28
Key Financial Figures
- $38.9000 —   Volume(s)     $38.9000   429     

Filing Documents
- a6380w.htm (6-K) — 366KB
- 0001654954-24-008954.txt ( ) — 367KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: July 16, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc